Kantarjian H - Search Results

1

Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.

Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Burger JA, et al. Among authors: kantarjian h. JCI Insight. 2017 Jan 26;2(2):e89904. doi: 10.1172/jci.insight.89904. JCI Insight. 2017. PMID: 28138560 Free PMC article.

2

Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone.

Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Anaissie E, et al. Among authors: kantarjian h. Ann Intern Med. 1992 Sep 15;117(6):466-9. doi: 10.7326/0003-4819-117-6-466. Ann Intern Med. 1992. PMID: 1354425

3

New drugs in the treatment of chronic lymphocytic leukemia.

Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. Keating MJ, et al. Among authors: kantarjian h. Leukemia. 1992 Nov;6 Suppl 4:140-1. Leukemia. 1992. PMID: 1359203 No abstract available.

4

Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis.

Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ. Robertson LE, et al. Among authors: kantarjian h. Blood. 1992 Jul 1;80(1):29-36. Blood. 1992. PMID: 1377051 Free article.

5

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Among authors: kantarjian h. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

6

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Keating MJ, et al. Among authors: kantarjian h. Leukemia. 1992;6 Suppl 2:78-80. Leukemia. 1992. PMID: 1578950 Review. No abstract available.

7

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Among authors: kantarjian h. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

8

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Among authors: kantarjian h. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

9

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Keating MJ, et al. Among authors: kantarjian h. J Clin Oncol. 1991 Jan;9(1):44-9. doi: 10.1200/JCO.1991.9.1.44. J Clin Oncol. 1991. PMID: 1702145 Clinical Trial.

10

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Among authors: kantarjian h. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,548 results

Search Page

Filters